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1232 The Journal of Thoracic and CardBackground: Patients with esophageal cancer who receive neoadjuvant chemora-
diotherapy are restaged with computed tomography (CT), endoscopic ultrasound
with fine needle aspiration (EUS-FNA), and integrated positron emission computed
tomography (FDG-PET/CT), and the results affect treatment.
Methods: This is a prospective trial on a consecutive series of patients who had
initial chest, abdomen, and pelvis CT scan; EUS-FNA; and fluoro-2-deoxy-D-
glucose (FDG)–integrated PET/CT; neoadjuvant chemoradiotherapy; repeat staging
tests; pathologic staging; and, if appropriate, resection with lymphadenectomy. The
primary objective was to assess the accuracy of these 3 tests in restaging patients
after neoadjuvant therapy.
Results: There were 48 patients (41 men), and 41 underwent Ivor Lewis esopha-
gogastrectomy with lymphadenectomy. The accuracy of each test for distinguishing
pathologic T4 from T1 to T3 disease is 76%, 80%, and 80% for CT scan, EUS-FNA
and FDG-PET/CT, respectively. The accuracy for nodal disease was 78%, 78%, and
93% for CT scan, EUS-FNA and FDG-PET/CT, respectively (P  .04). FDG-
PET/CT correctly identified M1b disease in 4 patients, falsely suggested it in 4
patients, and missed it in 2 patients, whereas for CT, it was 3, 3, and 3 patients.
Fifteen (31%) patients were complete responders, and FDG-PET/CT accurately
predicted complete response in 89% compared with 67% for EUS-FNA (P  .045)
and 71% for CT (P  .05).
Conclusions: FDG-PET/CT is more accurate than EUS-FNA and CT scan for
predicting nodal status and complete responders after neoadjuvant therapy in pa-
tients with esophageal cancer. FDG-PET/CT and CT alone provide targets for
biopsy, but results are often falsely positive.
Approximately 14,000 persons are given diagnoses of esophageal cancer eachyear in the United States, and 13,000 will eventually die of it.1 The 5-yearsurvival is stage dependent,2 and when surgical intervention alone is performed,
it ranges from 15% to 24%.3 Because of the poor results of resection alone, most
physicians in North America favor the use of neoadjuvant cisplatin-based chemoradio-
therapy. This bias is true despite the fact that there are few prospective randomized data
to support its routine use.4-9 Because surgical resection is often reserved for only those
who respond to their preoperative treatment or for those in whom disease does not
progress, surgeons are often asked to reassess patients for resection after neoadjuvant
therapy. The most commonly used staging modalities are computed tomography (CT)
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TSof the chest, abdomen, and pelvis; endoscopic ultrasonography
with fine-needle aspiration (EUS-FNA); and positron emission
tomography with fluoro-2-deoxy-D-glucose (FDG-PET). The
decision to operate or give more chemotherapy often hinges on
the interpretation of these tests. Thus we decided to evaluate
the accuracy of these tests for the determination of T stage,
nodal status, and distant M1 disease, as well as their ability to
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M1a or M1b disease underwent complete resection.
had T0 N1 disease.
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TShistory, physical examination findings, scan results, morbidity during
neoadjuvant therapy, and final pathology results were collected as
well. Separate forms were used to record the results of the CT,
EUS-FNA, and FDG-PET/CT and pathologic information as it be-
came available, and a blinded collector entered information prospec-
tively into an Access database (Microsoft, Seattle, Wash). Both the
prospective database used to store the data and this study were
approved by the Institutional Review Board of the University of
Alabama at Birmingham.
For inclusion in this study, requirements included the follow-
ing: biopsy-proved esophageal cancer; initial chest, abdomen and
pelvis CT, EUS-FNA, and FDG-PET/CT; neoadjuvant chemora-
diotherapy; repeat CT, EUS-FNA, and FDG-PET/CT; and patho-
logic staging. Patients with tissue confirmation of recalcitrant or
progressive nodal or metastatic disease who did not undergo
complete resection were also included in this study. Only magnetic
resonance imaging of the brain or bone was accepted as proof of
metastatic M1b disease; otherwise, tissue biopsy was required.
Patients who underwent resection had to have had lymphadenec-
tomy performed, as shown in Figure 1.
Patients were excluded if they did not have all 3 imaging tests
before esophagectomy; they underwent emergency esophagogas-
trectomy; they did not have repeat staging with an integrated
PET/CT scan; they did undergo chest, abdomen, and pelvic CT
with 5-mm columnated cuts with intravenous contrast; or they had
EUS-FNA performed by an endosonographer other than M.A.E.
After initial staging, all patients in this study underwent cisplatin-
based chemotherapy with concomitant radiotherapy. After the com-
pletion of their neoadjuvant treatment, patients were restaged with the
same 3 staging tests described below. A stage was assigned by using
the TNM staging classification system2 after each test. Because CT,
EUS-FNA, and FDG-PET could not differentiate T1, T2, or T3
disease, the accuracy for each test was assessed for its ability to
predict T1 to T3 disease from T0 and T4 disease. Because EUS-FNA
could not assess M1b disease (except for certain locations, such as the
left adrenal gland, the lower lobes of the lung, or parts of the liver), M
disease could be recorded as Mx disease.
CT Scans
All scans had to be performed on a third-generation machine or
greater, have 5-mm columnated cuts, and include the chest,
-FNA, and FDG-PET compared with pathology*
T status predicted by test
T0
EUS-FNA FDG-PET
Correctly predicted T0 in 3
patients
Correctly predicted T0 in
13 patients
1 4
0 0
eedle aspiration; FDG-PET, fluoro-2-deoxy-D-glucose–integrated positron
assessed. †This includes the 15 complete responders plus 1 patient whoTABLE 1. Patient characteristics
All patients (n  48)
Age, median (y) 68 (range, 48-76)
Sex
Male 41 (85%)
Female 7 (15%)
Types of radiation
5000 cGy 22 (46%)
5000 cGy 26 (44%)
Median duration between last date of
neoadjuvant therapy and:
Repeat CT 17 d
Repeat EUS 37 d
Repeat PET 27 d
Pathology
Adenocarcinoma 43 (85%)
Squamous cell carcinoma 5 (15%)
Stage of cancer before neoadjuvant
treatment
I (T1 N0 M0) 0
IIa (T2 N0 M0, T3 N0 M0) 22 (46%)
IIb (T0-2 N1 M0) 5 (10%)
III (T3 N1 M0) 15 (33%)
T4 (Any N M0) 2 (4%)
IV (M1a) 3 (6%)
IV (M1b) 1 (2%)
Stage of cancer after neoadjuvant
treatment
0 (Complete responder) 15 (31%)
I (T1 N0 M0) 5 (10%)
IIa (T2 N0 M0, T3 N0 M0) 10 (22%)
IIb (T0-2 N1 M0) 4 (8%)
III (T3 N1 M0) 2 (4%)
T4 (Any N M0)* 1 (2%)
IV (M1a) 5 (10%)
IV (M1b)* 6 (13%)
No. of patients who underwent Ivor
Lewis esophagogastrectomy
41† (88%)
CT, Computed tomography; EUS, endoscopic ultrasonography; PET,
positron emission tomography. *Two of the 6 patients with M1b disease
had resected pathologically confirmed T4 disease. †Some patients withTABLE 2. Results of T stage as predicted with repeat CT, EUS
Pathologic
results*
No. of patients with
this pathology CT
T0 16† Correctly predicted T0 in 4
patients
T1-T3 22 4
T4 3 0
CT, Computed tomography; EUS-FNA, endoscopic ultrasonography with fine-n
emission tomography. *Seven patients did not have their T status pathologicallye 2005
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TSabdomen, and pelvis. All films were read and interpreted by 1
of 4 chest radiologists. CT scans from outside institutions were
allowed, but they had to be reread at the University of Alabama
at Birmingham.
EUS-FNA
EUS was performed during conscious sedation, as previously
described,10 and all tests were performed by a single experi-
enced endosonographer (M.A.E.; 2500 EUS procedures). A
radial echoendoscope (GF-UM130; Olympus America,
Melville, NY) was first used to evaluate the presence or absence
of lymphadenopathy. The examination started with full evalu-
ation of the left lobe of the liver, the left adrenal gland (by
imaging it from the fundus of the stomach and then gradually
withdrawing it to evaluate the primary tumor), and all regional
echo-visible lymph nodes. The perigastric, subhepatic, and ce-
liac axis areas (M1a) were carefully evaluated for the presence
of adenopathy. Once a suspicious lymph node (the endosono-
graphic criteria for malignant lymph nodes involvement have
been previously described11) was identified, the radial echo-
endoscope was removed, and a curvilinear echoendoscope
(Olympus UC-30P or UCT 140) was inserted. EUS-FNA of the
target lesion or lesions was performed as previously de-
scribed.12 Peritumoral lymph nodes were not aspirated because
of the risk of contamination from the primary tumor.
All EUS-FNAs were performed with 22-gauge adjustable-
length Echotip needles (Wilson-Cook, Inc, Winston Salem, NC).
Cytological diagnosis of the aspirated lesion (either of suspicious
lymph nodes, M1a disease, or M1b disease) was reported as either
positive for metastatic cancer or negative. If regional lymph nodes
could not be aspirated because the primary tumor was intervening,
the ultrasonographic characteristics were used to call the node
positive or negative. The endosonographer (M.A.E.) was blinded
to the CT report and to the FDG-PET report.
FDG-PET/CT
FDG-PET/CT was performed on a dedicated PET scanner with an
integrated PET/CT system (GE Discovery LS PET/CT Scanner;
GE, Milwaukee, Wis). Patients were asked to fast for 4 hours and
then subsequently received 555 MBq (15 mCi) of FDG intrave-
nously, followed by PET after 1 hour. The most recent CT scan of
the chest was available for visual correlation of the integrated
T status pr
T1, T2, T3
CT EUS-FNA FDG-PET
12 13 3
Correctly predicted
T1-T3 in 18 patients
Correctly predicted
T1-T3 in 20 patients
Correctly predic
T1-T3 in 18 pa
2 3 1The Journal of ThoracicPET/CT result, but the reader (B.O.) was unaware of the EUS-
FNA–predicted TNM stage or of the TNM-predicted stage of the
CT scan.
Maximum standardized uptake value (maxSUV) was deter-
mined by drawing regions of interest on the attenuation-corrected
FDG-PET images around the primary tumor. The maxSUV was
calculated by using the software contained within the PET/CT
scanner and the following formula13:
MaxSUV
C(Ci ⁄ mL)
ID(Ci)
w(kg)
where C is defined as the activity at a pixel within the tissue
defined by a region of interest, and ID is defined as the injected
dose per kilogram of the patient’s body weight (w). The percentage
change of the maxSUV was calculated by using the following
formula:
MaxSUVintitialMaxSUVfinal
MaxSUVinitial
A regional lymph node (N disease or M1a disease if a celiac
node), as well as M1b disease, was considered positive on FDG-
PET/CT scanning if the maxSUV was 2.5 or greater and the
FDG-PET/CT report called the node malignant or highly suspi-
cious for malignancy. In this study M1a disease was defined as
celiac axis lymph node disease in patients with distal esophageal
tumors.
Statistical Analysis
Data were stored by using an Access database (Microsoft) and
analyzed with EpiInfo (CDC, Atlanta, Ga). Mortality was defined
as any death occurring during the hospital stay or within 30 days
postoperatively. Sensitivity, specificity, positive predicted value,
negative predicted value, and accuracy were determined for CT,
EUS-FNA, and FDG-PET/CT by using the pathology or biopsy
results as the gold standard. Standard definitions were used to
calculate these parameters.14 Differences between efficacy per-
centages were compared by using the test for proportions.
ed by test
T4
CT EUS-FNA —
0 0 0
s
0 1 0
Correctly predicted
T4 in 1 patient
Correctly predicted
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Correctly predicted
T4 in 2 patientsedict
ted
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Sixty-seven patients were eligible for this study over this
time frame. Four patients refused participation, and 9 pa-
tients were eliminated because after the completion of their
neoadjuvant therapy, they had evidence of progressive dis-
ease on the restaging tests but refused or did not undergo
tissue biopsy. In addition, 2 patients could not get repeat
FDG-PET/CT scans, and 4 patients were too ill or refused
resection. The remaining 48 patients make up the cohort of
this study. Patient characteristics are shown in Table 1.
There were 2 (4%) operative mortalities, and there was no
morbidity or mortality with EUS-FNA.
T Status
Table 2 depicts the results of the T status for CT, EUS, and
FDG-PET. As defined earlier, we allowed the endosonog-
rapher and radiologists to report a lesion as T1, T2, or T3
(because he could not differentiate tumor from posttreat-
ment effect), and his test results were considered correct if
the tumor was defined as T1, T2, or T3 on final pathology.
This definition was used for all 3 staging modalities. When
one evaluates the ability of a staging modality to correctly
distinguish pathologic T4 from T1 to T3 disease, the neg-
ative predictive value is 90%, 87%, and 95% and the accu-
racy is 76%, 80%, and 80% for CT, EUS-FNA, and FDG-
PET/CT, respectively. There were only 3 patients with T4
disease.
N Status
Chest CT, EUS-FNA, and FDG-PET/CT are all able to
predict the presence or absence of N status, M1a disease,
and complete responders. The raw data for each staging
modality is shown in Table 3, and the efficacy is seen in
Table 4. As shown, FDG-PET/CT is more accurate for
staging N disease than CT and EUS-FNA (93% and 78% vs
78%, respectively; P  .04).
M1a and M1b Disease
Six patients had pathologic M1a disease, and the results for
each test are shown in Tables 3 and 4. In addition, 6 patients
had M1b disease, and the results are shown in Table 5.
FDG-PET/CT found unsuspected M1b disease in 4 (8%)
patients, falsely suggested it in 4 (8%) others, and missed
small (4-mm) nodular implants in the lung and in the
omentum in 1 patient each.
Complete Responders
There were 15 (31%) patients who had a complete response
to neoadjuvant chemoradiotherapy. Table 4 compares the
efficacy among chest CT, EUS-FNA, and FDG-PET/CT for
complete responders (T0 N0 M0). FDG-PET/CT was more
1236 The Journal of Thoracic and Cardiovascular Surgery ● Junsensitive than EUS-FNA and CT (87% vs 20% vs 20%,
respectively; P  .01) and more accurate (89% vs 67% vs
67%, respectively; P  .045). When FDG-PET/CT over-
staged complete responders, all 3 patients had T1 N0 dis-
ease, whereas when EUS-FNA overstaged 12 of the 15
complete responders, it predicted T2 disease in 2 patients,
T3 disease in 7 patients, and T4 disease in 3 patients. CT
overstaged 11 of the 15 complete responders and predicted
T1 disease in 5, T2 disease in 4, and T3 disease in 2.
There were 23 patients who had biopsy-proved N1 dis-
ease before neoadjuvant therapy, and 8 of them had a
complete pathologic response. There were 25 patients
whose disease was staged as N0, and 7 were complete
responders.
Effect of Response to Chemoradiotherapy on Change
in MaxSUV
The median change in the maxSUV on FDG-PET/CT as
correlated to the pathology is shown in Figure 2. The
median percentage decrease in the maxSUV in the 36 pa-
tients who were downstaged (15 complete responders and
21 others) was significantly higher than for the 12 patients
who were not (47% vs 8%, respectively; P  .03).
Discussion
Despite the fact that few prospective randomized trials have
shown a benefit for neoadjuvant therapy for esophageal
cancer and some series that use esophageal resection alone
have adequate survival,15 most institutions use it. Thus the
interpretation of repeat staging tests affects the care of a
large proportion of patients with this aggressive cancer.
Patients who are deemed to have T4 disease or who have
recalcitrant nodal disease are often denied resection on the
basis of these test results. Yet there have been few prospec-
tive trials that have examined the accuracy of the 3 most
common staging and restaging tests, CT, EUS-FNA, and
FDG-PET, in one prospective study.
T Status
The accuracy of EUS-FNA for assessment of the T status
for esophageal cancer before chemoradiotherapy has been
well documented16 and is undisputed. It is minimally inva-
sive, has little morbidity, and can also obtain tissue to assess
N and M1a disease. At our institution, we have even been
able to prove M1b disease in selected areas, such as both the
right and left adrenal glands, the lower lobes of the lung,
and parts of the liver. However, its accuracy after neoadju-
vant therapy has been questioned.
Zuccaro and colleagues17 in 1999, Laterza and associates18
in 1999, and Beseth and coworkers19 in 2000 have all shown
that EUS-FNA cannot tell T1 from T2 or T3 disease after
chemoradiotherapy. However, Willis and colleagues20 in 2002
and Chalk and associates21 in 2000 showed that a 50% or
greater decrease of cross-sectional area, as determined by
e 2005
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distinction of T1 to T3 disease has little clinical importance
anyway because resection is invariably recommended for post-
therapy T1 to T3 lesions if patients have N0 disease. The
important clinical question is determining who has T4 disease
and perhaps should not undergo an operation because an R0
resection is not possible. Thus we evaluated the accuracy and
negative predictive value of the restaging tests to answer this
specific question. Because complete responders are a separate
category that might benefit the most from resection,22,23 they
were evaluated separately.
We were surprised to find that the negative predictive value
is best for FDG-PET/CT at 95%. This might be because our
study features an integrated PET/CT system as opposed to
dedicated PET alone. This might be an important distinction of
our study. We also found that none of the 3 tests were very
good for ruling out T4 disease. In fact, making the clinical
effect of our findings even more difficult to interpret is the fact
that we were able to completely resect all 3 patients who turned
out to have unsuspected T4 disease with negative margins.
EUS-FNA defined 1 patient’s disease as T3 and the other 2
patients’ diseases as T2. One might argue that these patients
had resectable T4 lesions, and thus EUS was correct in the
sense that they were resectable, but the clinical effect of re-
sected T4 versus nonresected T4 disease after neoadjuvant
therapy is unknown. Thus we recommend that if a patient’s
TABLE 3. Data used to compute efficacy for CT, EUS-FNA,
CT
True
positive
False
positive
False
negative
True
negative
True
positive
Fa
pos
N1 1 2 7 31 1
N0 31 7 2 1 31
M1a 0 0 6 42 2
CR 4 3 11 30 3
Note: N status was not pathologically assessed in 7 patients. CT, Computed
FDG-PET, fluoro-2-deoxy-D-glucose–integrated positron emission tomograp
cancer in celiac axis lymph node; CR, complete pathologic responders.
TABLE 4. Comparison of efficacy of CT, EUS-FNA, and FDG
Sensitivity Specificity Pos
CT EUS PET
P
value* CT EUS PET
P
value* CT
N1† 13% 13% 63% .12 94% 94% 100% .98 33%
N0† 94% 94% 100% .98 13% 13% 63% .12 82%
M1a 0% 33% 33% 1.00 100% 100% 98% 1.00 0%
CR 27% 20% 87% .01 91% 94% 88% .60 57%
CT, Computed tomography; EUS-FNA, endoscopic ultrasonography with
emission tomography; M1a, metastatic cancer in celiac axis lymph nod
pathologic responders. *P value refers to EUS-FNA versus FDG-PET. †Nrisk for surgical intervention is low, it makes sense to explore
The Journal of Thoracichim or her to attempt R0 resection, even if the staging tests
suggest T4 disease. More studies are needed to further examine
these important questions not answered in this trial.
Nodal Disease
Importantly, Rice and coworkers24 in 2001 showed that
patients with recalcitrant N disease after neoadjuvant
therapy have a 5-year survival of about 12% compared
with 37% in those who did respond. Thus the ability to
identify residual N disease also has clinical importance
because some surgeons might choose not to resect. We
FDG-PET
-FNA FDG-PET
False
negatives
True
negatives
True
positive
False
positive
False
negative
True
negative
7 31 5 0 3 33
2 1 33 3 0 5
4 42 2 1 4 41
12 31 13 4 2 29
graphy; EUS-FNA, endoscopic ultrasonography with fine-needle aspiration;
1, positive lymph nodes; N0, lymph nodes without cancer; M1a, metastatic
for nodal status, M1a disease, and complete responders
predictive value
Negative predictive
value Accuracy
PET
P
value* CT EUS PET P* CT EUS PET
P
value*
100% .14 82% 82% 92% .35 78% 78% 93% .04
92% .35 33% 33% 100% .14 78% 78% 93% .04
67% .98 88% 91% 91% 1.00 88% 92% 90% .76
76% .88 73% 67% 94% .04 71% 70% 88% .045
eedle aspiration; FDG-PET, fluoro-2-deoxy-D-glucose–integrated positron
, positive lymph nodes; N0, lymph nodes without cancer; CR, complete
was not assessed in 7 patients.
TABLE 5. Results of chest, abdomen, and pelvis CT and
FDG-PET for predicting M1b disease
True
positive
False
positive
False
negative
True
negative
CT PET CT PET CT PET CT PET
Location Not
applicableLiver 3 3 2 2 — —
Lung — 1 1 1 2 1
Adrenal — — — 1 — —
Omentum — — — — 1 1
CT, Computed tomography; FDG-PET, fluoro-2-deoxy-D-glucose–integrated
positron emission tomography.and
EUS
lse
itive
2
7
0
2
tomo
hy; N-PET
itive
EUS
33%
82%
100%
60%
fine-n
e; N1found that FDG-PET/CT is superior to EUS-FNA and CT
and Cardiovascular Surgery ● Volume 129, Number 6 1237
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metastatic nodal disease. EUS-FNA falters because of-
tentimes it cannot obtain aspirates from regional lymph
nodes because of intervening tumor. Moreover, the echo-
genic characteristics alone of a node might not be as
reliable after radiation as they are before. CT is inaccu-
rate because the radiologic response of a lymph node
often does not equate with the pathologic response. Thus
metabolic information blended with anatomic informa-
tion as afforded from an integrated PET/CT system, as
opposed to pure anatomic information from EUS-FNA or
CT, might be superior. We have already shown the ad-
vantage of integrated PET/CT over dedicated PET visu-
ally correlated with CT in a prospective randomized
study in patients with non–small cell lung cancer.25 Fi-
nally, if one believes that complete resection of recalci-
trant metastatic nodes is warranted and important, one
might be more likely to choose an Ivor Lewis instead of
a transhiatal approach for a patient with an FDG-PET/CT
result that suggests metastatic nodal disease.
FDG-PET results have been shown to be difficult to
interpret after radiotherapy, and the best time to repeat an
FDG-PET scan on a patient still remains unproved. In this
report the median time between the completion of radio-
therapy and the repeat FDG-PET/CT scan is 27 days. Our
numbers are too low to perform a dose-response or a time-
dependent analysis, but our preference is to wait at least 3
weeks before performing the second FDG-PET/CT scan.
Importantly, it must be stressed that a negative FDG-
PET/CT result of a regional lymph node after neoadjuvant
therapy is not proof of benignancy, nor is a positive FDG-
PET/CT result proof of cancer. It merely provides targets
for biopsy to rule out cancer.
The ability of FDG-PET (not necessarily FDG-PET/CT)
to discover unsuspected M1b disease is currently being
Figure 2. Median percentage decrease in maxstudied in a multi-institutional prospective trial under the
1238 The Journal of Thoracic and Cardiovascular Surgery ● Junguise of the American College of Surgeon’s Oncology
Group Trial Z0060. Pierre and colleagues26 in 2004 found
that FDG-PET upstaged 20% of 74 patients and correctly
downstaged 5%. However, he also found 7% false-positive
results and 4% false-negative results. In this series we found
that FDG-PET/CT discovered M1b disease in 4 (8%) pa-
tients but was also falsely positive in 4 (8%) patients. The
results of Z0060 might provide answers as to the staging
advantages provided by FDG-PET for M1 disease and bal-
ance them against the increased cost and morbidity of
investigating false-positive results.
Complete Responders
Patients who undergo complete resection and who are
found to be complete responders have a favorable prog-
nosis.22,23 In our series 15 (31%) of the 49 patients were
complete responders, and EUS-FNA overstaged all but 3
of them. Interestingly, Zuccaro and associates17 in 1999
reported almost an identical incidence of complete re-
sponse rate and rate of overstaging for EUS. The quan-
titative assessment of tumor metabolism by means of
FDG-PET with maxSUV is a relatively new and exciting
noninvasive technique to monitor a patient’s metabolic
response to a therapy. We found this objective measure-
ment of metabolic activity to be more accurate than the
change in a tumor’s size. As we and others have shown,
a significant decrease in the maxSUV in patients with
non–small cell lung cancer27 better correlates with a
complete response than the change in size on CT or the
absolute value of the maxSUV on repeat FDG-PET. This
series, like those from Kato and coworkers28 and Downey
and colleagues29 in 2002 suggest that this is also true in
patients with esophageal cancer.
There are strengths and weaknesses to our study. Most
of the previous studies evaluate the accuracy of a single
on repeat FDG-PET after neoadjuvant therapy.SUVmodality over a long time period. This study offers a
e 2005
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same patient population over a short 2-year period using
the best currently available technology and experienced
readers. This might minimize confounders because of
alterations in clinician experience, assignment of stage by
multiple clinicians, and changes in technology. However,
our study has a relatively small sample size, has been
performed in a single institution only by one surgeon, and
has only 3 patients with T4 disease, 5 with proved M1a
disease, and 6 with M1b disease. Moreover, the strict
entry criteria to this study, which required biopsy proof
of progressive disease, eliminated 9 patients. Most of
these patients had EUS-FNA that showed T4 nonresect-
able tumors, but because there was no pathologic proof of
T4 disease (these patients could have all been in
pathologic T0 stage), they were not included in this
study. This rigid design might have negatively affected
the true benefit of EUS-FNA. A multi-institutional trial is
needed.
Recommendations
On the basis of the data presented above, as well as our
experience, we recommend the following algorithm. We
favor a repeat FDG-PET/CT scan (or, if not available, a
CT scan of the chest, abdomen, and pelvis) to be per-
formed no sooner than 3 to 4 weeks after the completion
of the preoperative chemoradiotherapy. If FDG-PET/CT
is available and if an initial FDG-PET/CT scan has been
performed and all suspicious sites have undergone bi-
opsy, we prefer it to CT. All possible M1b disease should
be identified on either FDG-PET/CT, CT, or both, and all
sites should be further investigated unless the lesion was
initially investigated and has not changed. If M1a or M1b
disease (in EUS-FNA obtainable areas) is suspected, we
then recommend performing EUS-FNA to biopsy these
areas, as well as to assess the T and N status. If no M1a
or M1b disease is suggested, we still prefer repeat EUS-
FNA to assess the T status, as well as to obtain tissue of
any residual N disease, despite the fact that our data do
not prove its full usefulness for the T status. However, if
a complete pathologic response is suggested by FDG-
PET/CT, then EUS-FNA adds little.
Conclusion
The surgeon must be aware of the limitations of each
restaging modality. CT, EUS-FNA, and FDG-PET/CT can-
not reliably differentiate the T status of esophageal cancer
after neoadjuvant therapy, except for FDG-PET for T0
disease. None can reliably rule out T4 disease. FDG-
PET/CT is superior to both chest CT and EUS-FNA for
predicting nodal disease, and it is also better for predicting
complete responders.
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Discussion
Dr Steven DeMeester (Los Angeles, Calif). I would like to
congratulate Dr Cerfolio both on his excellent presentation and
the comprehensive article that he and his colleagues have
prepared. The aim or objective of this study was to compare the
accuracy of 3 modalities for restaging esophageal cancer after
neoadjuvant therapy. Because neoadjuvant therapy is com-
monly used in the treatment of patients with esophageal cancer,
this study is relevant, and the 3 modalities compared—CT,
PET, and endoscopic ultrasonography—are available at most
centers, and therefore the study objective is worthwhile. How-
ever, how this information should be used in practice is less
clear. After neoadjuvant therapy, 75% to 80% of patients will
have residual disease, and one could argue that precise local
restaging is less important than just ruling out systemic meta-
static disease, particularly because the goal or plan with neo-
adjuvant therapy is to follow up with surgical resection. I have
several questions for Dr Cerfolio.
First, I have some questions pertaining to the details of PET
scanning. Your patients all underwent PET scanning, as you
pointed out, with the integrated PET/CT system. Presumably, this
is what allowed the differentiation of the T stage of the tumor. Can
you elaborate on how exactly PET/CT was used to determine the
T stage, and in the absence of a fusion CT/PET system at a center,
is it still possible to use PET scanning to define T stage?
Second, why were all 3 tests so poor at accurately identifying
T4 tumors? And because the 3 patients with T4 tumors in your
series all underwent successful surgical resection anyway, how
important is it to determine the T stage after neoadjuvant therapy?
Third, all 3 tests were associated with false-positive and false-
negative assessment of nodal metastases, and this is in the setting
of a study within an academic center. Out in the real world,
accuracy rates are almost certain to be lower. What do you believe
are acceptable accuracy rates when the results are going to be used
for important patient management decisions?
Fourth, recent studies with either minimally invasive staging
techniques or EUS-FNA have suggested that complete pathologic
response rates with neoadjuvant therapy are lower in patients with
pretherapy pathologically confirmed N1 disease. What percentage
1240 The Journal of Thoracic and Cardiovascular Surgery ● Junof patients with pathologically confirmed N1 disease had a com-
plete response to neoadjuvant therapy in your series?
Fifth, why was the positive predictive value for complete
response so poor and not significantly different with the 3 modal-
ities? You did not present that; instead, you focused on negative
predictive value. But is the positive predictive value not more
important in this circumstance?
Sixth, there were 4 patients with true-positive results with
systemic metastases found by fusion CT/PET scanning after neo-
adjuvant therapy, but there were 8 patients with false-positive or
false-negative scan results. Because the number of false positive
and false-negative PET scan results exceeded the true-positive
results, is PET even worthwhile for assessing systemic metastatic
disease after neoadjuvant therapy, or should we just be using CT,
especially because most metastases were either in the lung or the
liver, areas that are very well seen with computed axial tomogra-
phy?
Lastly, do you have any information on the relative cost or
cost/benefit ratio of each of these tests? And if you were at a center
and had only the option of picking one test, which one would it be?
Dr Cerfolio. Thank you very much, Dr DeMeester. For time’s
sake, we might have to finish some of these questions over a beer
later, but I will try to answer them all as quickly and succinctly as
possible.
Your first question was as follows: Can PET tell us about T
status, as opposed to PET/CT? I do not think it can. I think with the
enhanced spatial resolution of integrated PET/CT, you can at least
get an idea of the T status, like you can on a computed axial
tomographic scan, but as we all know, it is not very good. The
esophagus looks thickened. You do not know what is residual
cancer and what is fibrotic, but neither does the endosonographer
with EUS, as we found out in this study.
Second, you asked about the patients with T4 disease and
why the modalities were so poor with that. I cannot tell you.
Perhaps because this is a surgical series that required resection
as an entry criterion, some T4 diseases were eliminated. Per-
haps there is a difference between respectable T4 disease
(thought to be T3 disease in this series or we probably would
not have offered surgical intervention) than nonresectable T4
disease. The very rigorous design meant that 9 patients were
eliminated; 7 of them had EUS criteria that showed T4 disease.
Because I could not prove that the EUS was right, I could not
include them in this study. They could have been complete
responders, and the endosonographer could have been wrong,
but those patients were not included.
The third question was about the false-positive and false-
negative results for nodal status. This is an important finding,
especially for our medical colleagues. Just because a node is
positive on a CT scan or PET scan, whether a patient has lung
cancer or esophageal cancer, only means a biopsy of that lesion
is required. Because EUS oftentimes cannot traverse the pri-
mary to get to the peritumoral lymph nodes to assess the node
and because the echogenicity of the node after radiation and
chemotherapy might not be a good predictor of malignancy or
benignancy as it is before chemoradiotherapy, once must keep
this in mind when interpreting the results of the restaging tests.
The fourth question concerns the complete responders. There
were 15 complete responders; 8 patients were initially staged as
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had biopsy-proved N1 disease initially.
The fifth question concerns why we reported the high negative
predictive value and not the low positive predictive value. Actu-
ally, we report both, but the positive predictive value reflects
prevalence of disease, and for this article, with a relatively small
number of patients, it might not be as important.
Your sixth question concerns the role of PET for M1b disease.
As we all know, there is a Z60 multi-institutional trial going on
that is better able and equipped to accurately answer that question
than this current series. We have placed more than 25 patients in
that trial. One has to consider the cost of chasing after false-
positive results with extra scans and the anxiety that it causes
patients versus identifying new M1b disease and avoiding unhelp-
ful resections. I believe it is worthwhile, but I await the results of
the Z60.
Finally, as to the costs and what we recommend, as I showed in
one of the slides, we recommend an integrated PET/CT scan. Not
only does it better identify N1 disease than EUS but it also allows
one to generate the change in maxSUV, which we believe is an
important predictor of pathologic response. Our future is clearly
PET/CT and not PET, and I think that is what all of us will have,
at least in North America.
Dr Richard Whyte (Stanford, Calif). I have one quick ques-
tion. You ran through some of those slides very quickly, but I think
somewhere there you said that patients with a complete response
benefit from an operation.
Dr Cerfolio. Thank you. I said “might” benefit the most from
resection, although some believe they might not even require
resection.
Dr Whyte. “Might” benefit. I wanted you to expound on that a
little bit because if you really have a pathologic compelte response,
do you benefit from an operation at all?
Dr Cerfolio. That is a great question and one that requires a
prospective randomized trial to accurately answer. What you
are saying is what we just talked about last week at one of our
conferences, and that is the question of whether a patient who
has a complete response benefits from esophagectomy? The real
The Journal of Thoracicquestion in the past has been how one knows who is a complete
responder without resecting them? I believe that we now have
presented data with the maxSUVs as a way of getting a good
idea of who these patients are. It is not the absolute value of the
repeat PET scan. It is the percentage decrease of the maxSUV.
In our article on lung cancer, which is coming out in Annals
later this year, we found it was a decrease of greater than 80%
that predicted a complete response. In this study it was a
decrease of about 50% or 60% as a good predictor of complete
response. Now for the first time, maybe we can ethically do that
study and randomize patients with a significant decrease in the
maxSUV and who are undergoing a repeat EUS and CT scan
that show a complete response and randomize these patients to
observation or resection. Until that study is done, I cannot fully
answer your question. At least now we have a way to identify
potential patients for the study.
Dr Stephen Yang (Baltimore, Md). Just to follow up on Rich’s
comment, how many patients had a negative CT scan result and a
negative PET/CT scan result? And when you present those data to
the patient—the CT result is negative and the PET result is
negative—how do you convince them to go on for a surgical
operation?
Dr Cerfolio. Thank you. Well, I think of that up front, and
therefore I tell them before they get their treatment that I have no
data that even if they have a wonderful response that they should
not undergo an operation. Thus I have them geared up for it
preoperatively. We tell them we hope and pray that they get a great
response, but they might not benefit from that without esophagec-
tomy. I tell them I do not have definitive data to prove that, but that
is my opinion and my belief. We have had 3 patients refuse
operations because of this perceived clinical complete response,
and all 3 have come back within 12 months with recurrent local
disease and 1 with M1b disease. Until I see some data otherwise,
that is practice and is what I am going to continue to tell them. I
do not see why esophagectomy would be different from other
cancers. If one can offer a safe operation and completely resect all
disease, I believe that is best.
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